Home > Healthcare > Biotechnology > Biotechnology R&D > Automated Cell Counter Market

Automated Cell Counter Market Trends

Report ID: GMI5352
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Automated Cell Counter Market Trends

Increasing R&D investments worldwide to cater to the higher need for efficient diagnostic solutions due to the surging burden of diseases is expected to boost the market prospects. The advent of serious infectious diseases, including COVID-19 and the Ebola epidemic has further increased the demand for research activities globally. It has been reported that the U.S. is one of the top nations for spending on R&D followed by China and Japan and spent more than USD 679 billion on domestic R&D projects in 2022.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Automated cell counter industry size was worth USD 6.3 billion in 2022 and is set to witness over 5.5% CAGR by 2032 driven by the rising prevalence of chronic and infectious diseases.

The fluorescence image-based cell counter segment is estimated to witness 5.3% CAGR by 2032 owing to the rising number of people suffering from UTIs, kidney diseases, and diabetes.

North America held over 37.9% of the market share in 2022 and is estimated to be worth USD 3.8 billion by 2032 attributed to the presence of well-established healthcare infrastructure and research facilities in the region

Olympus Corporation, Thermo Fisher Scientific Inc, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, Sysmex Corporation, NanoEnTek, F. Hoffmann-La Roche Ltd, Danaher (Beckman Coulter Inc. and Radiometer), and Agilent Technologies, Inc. are some top enterprises in the market.